Domain Associates, L.L.C., established in 1985 and headquartered in Princeton, New Jersey, is a venture capital firm that specializes exclusively in the life sciences sector. With $2 billion in capital under management, the firm focuses its investments on pharmaceuticals, specialty pharmaceuticals, medical devices, diagnostics, and other evolving areas within the life sciences industry. Domain Associates has a strong track record, with its partners collectively possessing nearly 200 years of experience in healthcare and venture capital, contributing to the formation and growth of over 200 life sciences companies. The firm also has an office in San Diego, California, which aids in broadening its investment reach across the United States. Through its extensive network and expertise, Domain Associates has established itself as a prominent player in the healthcare investment landscape.
Nobias Therapeutics is a developer of rare pediatric disease drugs intended to cure rare illnesses in children. It focuses on discovering the genetic basis for rare diseases and develops drugs that can intervene in the affected pathways, enabling parents to help their infants become healthier.
WindMIL Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer patients, utilizing insights from bone marrow immunology. Established in 2015 and based in Princeton, New Jersey, the company specializes in a novel class of therapies known as Marrow Infiltrating Lymphocytes (MILs). These therapies are derived from memory T cells found in the bone marrow and involve reactivating dormant T-cells to create effective immunotherapies. By harnessing the unique immunologic properties of bone marrow, WindMIL Therapeutics aims to provide life-saving treatment options for individuals battling cancer.
Tobira Therapeutics, Inc. is a biotechnology company focused on the research, development, and commercialization of antiviral compounds aimed at treating serious infectious diseases. Founded in 2006 and based in Princeton, New Jersey, the company specializes in the development of TBR-652 and TBR-220 antagonists, which are designed for the treatment of HIV/AIDS, hepatitis, and other related infectious conditions. Through its innovative approach, Tobira Therapeutics aims to address critical health challenges associated with these diseases.
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
Tobira Therapeutics, Inc. is a biotechnology company focused on the research, development, and commercialization of antiviral compounds aimed at treating serious infectious diseases. Founded in 2006 and based in Princeton, New Jersey, the company specializes in the development of TBR-652 and TBR-220 antagonists, which are designed for the treatment of HIV/AIDS, hepatitis, and other related infectious conditions. Through its innovative approach, Tobira Therapeutics aims to address critical health challenges associated with these diseases.
Esprit Pharma
Series B in 2007
Esprit Pharma is a pharmaceutical company focused on specialty therapeutics and committed to improving patient well-being in the urology and OB/GYN areas by providing products that contribute to bettering patient outcomes.
Esprit Pharma
Series B in 2006
Esprit Pharma is a pharmaceutical company focused on specialty therapeutics and committed to improving patient well-being in the urology and OB/GYN areas by providing products that contribute to bettering patient outcomes.
Esprit Pharma
Series A in 2005
Esprit Pharma is a pharmaceutical company focused on specialty therapeutics and committed to improving patient well-being in the urology and OB/GYN areas by providing products that contribute to bettering patient outcomes.
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
OraPharma is a specialty pharmaceutical company focused on developing and commercializing products that enhance oral health. The company is known for its innovative approach to treating periodontal disease, particularly through its flagship product, ARESTIN® (minocycline HCl) Microspheres, a locally administered antibiotic that utilizes patented microsphere technology. This product is designed to be used as an adjunct to scaling and root planing, offering a targeted solution for various stages of periodontal disease. OraPharma is committed to educating dental professionals and consumers about periodontal health and continues to advance the field with scientifically and technologically driven solutions tailored for dental practices in the United States.
NPS Pharmaceuticals is a biopharmaceutical company focused on developing therapeutic products for gastrointestinal and endocrine disorders, particularly for patients with rare diseases. The company’s leading products include Gattex and Revestive, which are used for treating adult patients with short bowel syndrome who rely on parenteral support. Additionally, NPS Pharmaceuticals has developed Natpara, a bioengineered parathyroid hormone for managing hypoparathyroidism, and is conducting clinical studies for NPSP795, a treatment for Autosomal Dominant Hypocalcemia. The company is committed to addressing significant unmet medical needs and has established a global pipeline of innovative therapies. NPS Pharmaceuticals operates in various regions, including the U.S., Canada, Europe, Latin America, and Japan, and collaborates with several major pharmaceutical companies to enhance its research and development efforts. Founded in 1986 and based in Bedminster, New Jersey, NPS Pharmaceuticals aims to transform the lives of patients with rare diseases through its focused therapeutic initiatives.
Genta Incorporated is a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of people with cancer. Genta has built a broad portfolio of proprietary products in various stages of clinical development. The Company’s drugs include Ganite (gallium nitrate injection), tesetaxel, and oral gallium.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.